Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

G. Garcia-Manero, S. D. Gore, S. Kambhampati, B. Scott, A. Tefferi, C. R. Cogle, W. J. Edenfield, J. Hetzer, K. Kumar, E. Laille, T. Shi, K. J. MacBeth, B. Skikne

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes'. Together they form a unique fingerprint.

Medicine & Life Sciences